US-funded scientists said Thursday they have devised an experimental vaccine against a common childhood illness called respiratory syncytial virus (RSV).

There is currently no vaccine on the market for RSV, which is the world's second-leading killer of babies aged one month to one year, after malaria.

RSV causes inflammation in the small airways of the lungs and is the most common cause of pneumonia in babies and of hospitalization of children under five.

“Many common diseases of childhood are now vaccine-preventable, but a vaccine against RSV infection has eluded us for decades,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.

“This work marks a major step forward," he said, citing promising animal studies that showed a wide-ranging protective effect.

Planning is under way for human trials of the vaccine.

The research on the vaccine and its structure-based design is described in the journal Science.

About News.net

Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.

 

FAQs

Email

If you have any questions or concerns please email us on support@news.net

Phone

  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.

Cancel